Mikaël Mazighi, Martin Köhrmann, Robin Lemmens, Philippe A Lyrer, Carlos A Molina, Sébastien Richard, Danilo Toni, Yannick Plétan, Anouar Sari, Adeline Meilhoc, Martine Jandrot-Perrus, Sophie Binay, Gilles Avenard, Andrea Comenducci, Jean-Marie Grouin, James C Grotta
BACKGROUND: Antagonists of glycoprotein VI-triggered platelet activation used in combination with recanalisation therapies are a promising therapeutic approach in acute ischaemic stroke. Glenzocimab is an antibody fragment that inhibits the action of platelet glycoprotein VI. We aimed to determine and assess the safety and efficacy of the optimal dose of glenzocimab in patients with acute ischaemic stroke eligible to receive alteplase with or without mechanical thrombectomy. METHODS: This randomised, double-blind, placebo-controlled study with dose-escalation (1b) and dose-confirmation (2a) phases (ACTIMIS) was done in 26 stroke centres in six European countries...
February 2024: Lancet Neurology